13-Nov-2020 - Evotec SE

Evotec expands Oxfordshire site into a fully-integrated R&D centre

"Dorothy Crowfoot Hodgkin Campus"

Evotec SE announced the expansion of the Company’s existing campus based at Milton Park in Abingdon, Oxfordshire, UK, into a major, fully-integrated, co-located discovery and development centre to be named Dorothy Crowfoot Hodgkin Campus. Adding a new building, which will house up to 100 biologists by the end of the year, will bring together all the key functions for cutting-edge and high-performance small molecule discovery and up to commercial development.

The Dorothy Crowfoot Hodgkin Campus will boast the co-location of in vitro pharmacology and protein sciences, structural biology, drug metabolism and pharmacokinetics, computational, synthetic, and medicinal chemistry, formulation sciences, development chemistry and API manufacture. The co-location of these critical scientific functions enables excellent communication and rapid and inventive problem-solving at the interfaces of disciplines as well as accelerating the speed of iterative cycles in the drug discovery and development processes, turning the site into a fully integrated R&D centre.

Evotec’s campus at Milton Park already benefits from the strong relationships and proximity with the Diamond Light Source at Harwell, making it a centre of excellence in structure-based drug design. The location also facilitates excellent partnership opportunities in the Oxford and UK-wide academic and biotech scene. 

With over 600 employees on site, Evotec’s Dorothy Crowfoot Hodgkin Campus now joins Evotec’s sites in Toulouse and Verona as one of three fully integrated powerhouses of capacity, capabilities and know-how in integrated R&D for the benefit of its partners.

Dr Craig Johnstone, Chief Operating Officer of Evotec, said: “Successful, fully-integrated drug discovery and development requires know-how and expertise as well as cutting-edge technologies and capabilities. We are delighted to extend our breadth of fully-integrated R&D sites with this extension to our capabilities at our Abingdon site, which we are proud to name after the X-ray crystallography technology leader and Nobel laureate: Dorothy Crowfoot Hodgkin Campus.”

Facts, background information, dossiers
  • Evotec
  • research and development
More about Evotec
  • News

    Evotec achieves milestone in its neurodegeneration collaboration with Bristol Myers Squibb

    Evotec SE announced that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company within the companies’ iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb’s decision to add another drug discovery project to the partnership’s portfolio. Evotec a ... more

    Evotec and Sartorius partner with start-up Curexsys on iPSC-based exosome approach

    Evotec SE Sartorius announced that they have entered into a partnership with the recently established Curexsys GmbH, a Goettingen, Germany-based technology leader specialising in the emerging field of therapeutic exosomes. Curexsys delivers a proprietary isolation technology for exosomes ba ... more

    Evotec and Novo Nordisk form alliance to develop novel therapies for kidney diseases

    Evotec SE and Novo Nordisk announced a strategic collaboration on the discovery and development of innovative therapeutics for patients with chronic kidney disease. Evotec and Novo Nordisk will jointly identify and develop novel targets based on comprehensive medical and molecular data sets ... more

  • Companies

    Evotec SE

    Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more

    Evotec Neurosciences GmbH

    Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is b ... more